Board of Directors
Founded in 2011 by ex-Pfizer R&D executives and healthcare entrepreneurs, Thetis Pharmaceuticals LLC is a biopharmaceutical company developing novel lipid-based drug candidates for the treatment of orphan gastrointestinal diseases with high unmet medical needs.
Mr. Ogier co-founded Acetylon in October 2008 and was appointed its founding President and Chief Executive Officer and a Director of the company in July 2009 at the time of its Series A financing. Mr. Ogier has raised more than $250 million in private and public company financing during his 20+ year life science industry career and has brought more than a dozen therapeutic products to market in North America and Europe. From 1997 to 2007, he served as President and CEO of development stage companies Eligix, Inc., Genetix Pharmaceuticals, and Arbios Systems Inc. He was previously Vice President of Marketing with Aastrom Biosciences, Inc., which he helped to bring public in 1997 (Nasdaq: ASTM), and earlier in his career held various product management, global marketing and business development positions within the Blood Therapy Group of Baxter Healthcare Corporation. Mr. Ogier’s industry experience spans development of small molecule drugs, monoclonal antibodies, growth factors, adult stem cell and immune cell therapies, gene therapies, bone marrow and solid organ transplantation, therapeutic medical devices and blood diagnostics with a focus on blood-related diseases including hematologic cancers, inflammatory / autoimmune diseases and genetic blood disorders. Mr. Ogier received his M.B.A. from the Yale School of Management and B.A. in chemistry magna cum laude from Williams College.
Mr. Wurzer is Executive Vice President and Chief Investment Officer at Connecticut Innovations Inc., a leading early stage life science investor nationwide. Prior to joining CI, Mr. Wurzer had extensive senior-level experience in operations and finance, including more than 10 years as executive vice president, treasurer and CFO of CuraGen Corporation (NASDAQ: CRGN), where he guided the company through its initial public offering, raising more than $700 million, and through the negotiation of strategic and business development alliances with Roche, Bayer and Abgenix. He helped to grow CuraGen and its technology development subsidiary into an operation with more than 500 employees and a market capitalization as high as $5.3 billion. Dave began his professional career with Coopers & Lybrand in Hartford, Connecticut.
Mr. Willson is President & CEO of ITF Pharma, Inc. and is co-founder and chairman of Hsiri Therapeutics, LLC, a start-up company focused on the development of new antibiotics for drug-resistant infections. He was formerly the President & CEO of Cytokine PharmaSciences, Inc., a biopharmaceutical company focused on women’s health, inflammation and cancer. As one of Cytokine founders, Mr. Willson spent 19 years in leadership positions managing the successful development and licensing of several products, including Cervidil, one of the world’s leading obstetric products. In October 2011, Mr. Willson led the company in a strategic sale to Ferring S.A. Before joining Cytokine, Mr. Willson held management, finance and business development positions at Abbott Laboratories Rorer International, and Carrington Laboratories. Mr. Willson graduated summa cum laude from the University of Notre Dame with a degree in psychology and modern languages and has a law degree from the University of California, Hastings College of the Law.
Mr. Mathias has more than 25 years of experience in the healthcare industry as an entrepreneur, investor and banker. For 15 years prior to joining Thetis full-time as CEO, Mathias was a senior partner at Carter Morse & Mathias, a boutique investment banking firm based in Southport, Connecticut. He previously was a senior vice president in the Healthcare Group at GE Equity Capital, Chief Operating Officer of Diabetes Support Systems, and executive vice president of Premier Healthcare, an healthcare focused private equity firm. Mr. Mathias has an MBA from the Yale School of Management, a BA in Economics from Harvard College, and was a Fulbright Fellow in economic development.
Dr. Sciavolino has extensive experience in the pharmaceutical industry including a distinguished 35 year career at Pfizer Global R&D where he held various management roles and responsibilities in R&D operations including drug discovery, development, registration and licensing. Dr. Sciavolino served as Director of R&D operations at Pfizer, where he led the discovery of Zithromax and played a major role in the COX-2 technology and Celebrex development and registration. He also had a leadership role in setting up Pfizer’s R&D operations in Japan. Dr. Sciavolino has served on numerous editorial boards including Annual Reports in Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and the Journal of Antibiotics. Dr. Sciavolino has more than 30 issued patents and has a Ph.D. in organic chemistry from the University of Michigan and B.S. in Pharmacy from St. John’s University.